Home/Pipeline/IBI-326

IBI-326

Multiple Myeloma

Phase 1/2Active

Key Facts

Indication

Multiple Myeloma

Phase

Phase 1/2

Status

Active

Company

Innovent Biologics

About Innovent Biologics

Innovent Biologics' mission is to develop and commercialize high-quality, innovative medicines that are affordable and accessible to patients worldwide. Its key achievements include a successful 2018 Hong Kong IPO, the commercialization of multiple blockbuster products like Tyvyt® (sintilimab), and the establishment of a deep, diversified pipeline through internal R&D and strategic partnerships. The company's strategy hinges on full integration, global expansion, and leveraging its robust technology platforms to deliver a sustainable portfolio of novel biologics.

View full company profile

Therapeutic Areas

Oncology Metabolic Disorders Autoimmune Diseases

Other Multiple Myeloma Drugs

Drug	Company	Phase	Status
Tasquinimod	Active Biotech	Preclinical	Active (Academic Partnership)
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
Kyprolis® (carfilzomib)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
inobrodib (CCS1477)	CellCentric	Phase 1/2	Active
ISB 2001	Ichnos Glenmark Innovation	Phase 1b	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Hemady	Dexcel Pharma USA	Approved	Commercial
AV-353	AVEO Oncology	Pre-clinical	Active
Sequesta™	ID4Pharma	Pre-clinical	Active
Myeloma Consortium	Criterium	Unknown	Active
GPRC5D x CD3 TCE	Integral Molecular	Preclinical	Available for License
RORA-Tscm CAR-T	RORABio	Pre-clinical	Active